The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing
In: Bioorganic & medicinal chemistry letters (Print), Jg. 18 (2008), Heft 24, S. 6369-6373
academicJournal
- print, 16 ref
Zugriff:
The development of a novel series of imidazole pyrimidine amides as cyclin-dependent kinase (CDK) inhibitors is described. Optimisation of inhibitory potency against multiple CDK's (1, 2 and 9) resulted in imidazole pyrimidine amides with potent in vitro anti-proliferative effects against a range of cancer cell lines. Excellent physiochemical properties and large margins against inhibition of CYP isoforms and the hERG ion channel were achieved by modification of lipophilicity and amine basicity. A candidate with disease model activity in human cancer cell line xenografts and with suitable physiochemical and pharmacokinetic profiles for intravenous (iv) dosing was selected for further development as AZD5597.
Titel: |
The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing
|
---|---|
Autor/in / Beteiligte Person: | JONES, Clifford D ; ANDREWS, David M ; MCFARLAND, Heather M ; MCGREGOR, Alexandra ; MOSS, Louise ; RUDGE, David A ; SIMPSON, Peter B ; SWAIN, Michael L ; TAM, Kin Y ; TUCKER, Julie A ; WALKER, Mike ; BARKER, Andrew J ; BLADES, Kevin ; DAUNT, Paula ; EAST, Simon ; GEH, Catherine ; GRAHAM, Mark A ; JOHNSON, Keith M ; LODDICK, Sarah A |
Link: | |
Zeitschrift: | Bioorganic & medicinal chemistry letters (Print), Jg. 18 (2008), Heft 24, S. 6369-6373 |
Veröffentlichung: | Amsterdam: Elsevier, 2008 |
Medientyp: | academicJournal |
Umfang: | print, 16 ref |
ISSN: | 0960-894X (print) |
Schlagwort: |
|
Sonstiges: |
|